InStem And Curie Institute Scientists Develop Molecular Sensor To Detect Cancer Drugs

Mumbai : The Institute for Stem Cell Science and Regenerative Medicine (InStem), Bengaluru in collaboration with Curie Institute, Orsay, France, has developed a molecular sensor, which can identify cancer drugs by detecting how such chemicals modify microtubules inside living cells.

Microtubules are part of the cytoskeleton, a structural network within the cell’s cytoplasm, and they alter in response to several chemicals.

“Understanding tubulin modifications have remained a challenge till date because of unavailability of tools that can mark them in living cells. Both the researchers have overcome this shortcoming and developed the first tubulin nanobody – or sensor to study the dynamics of microtubule modifications in living cells and use this for identification of new cancer therapeutic drugs”, said the statement issued by the Department of Science and Technology (DST).

The researchers from Bengaluru and Orsay devised a method to design synthetic proteins, known as nanobodies, which can bind specifically to modified microtubules. These nanobodies are similar to antibodies made in our body as a defense mechanism against pathogens. However, unlike antibodies, the nanobodies are smaller in size and easily amenable for protein engineering. The nanobody was then coupled with a fluorescent molecule to serve as a detection tool, called sensor. They developed and validated a live cell sensor against a unique microtubule modification called tyrosinated form of microtubules that is already known to be important for cell division and intracellular organization.

The tyrosination sensor is the first tubulin nanobody – or sensor – that can be used to study the dynamics of microtubule modifications in living cells. Indo-French Centre for the Promotion of Advanced Research (IFCPAR/CEFIPRA) researchers has shown the application of this sensor in studying the effect of small-molecule compounds that target microtubules. These chemicals are frequently used as anti-cancer drugs. Thus, the tyrosination sensor will facilitate studying microtubule functions for many researchers and will aid identifying new drugs of therapeutic value.

  • Related Posts

    DCGI Cracks Down On 90 Unapproved Fixed-Dose Combinations: Cough Syrups, Vitamins, Diabetes Drugs Among Those Flagged For Sale Without Central Approval

    New Delhi — India’s top drug regulator has issued a nationwide alert over 90 fixed-dose combination (FDC) drugs being manufactured and sold without mandatory central approval, directing all state and…

    India’s drug body flags 90 unapproved FDC medicines, states told to take action

    The Central Drugs Standard Control Organisation (CDSCO), India’s top drug regulator, has identified at least 90 unapproved fixed-dose combination (FDC) medicines in circulation and asked states to move against those…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    DCGI Cracks Down On 90 Unapproved Fixed-Dose Combinations: Cough Syrups, Vitamins, Diabetes Drugs Among Those Flagged For Sale Without Central Approval

    DCGI Cracks Down On 90 Unapproved Fixed-Dose Combinations: Cough Syrups, Vitamins, Diabetes Drugs Among Those Flagged For Sale Without Central Approval

    India’s drug body flags 90 unapproved FDC medicines, states told to take action

    India’s drug body flags 90 unapproved FDC medicines, states told to take action

    India advancing as a global hub of affordable, quality healthcare solutions: Dr Jitendra Singh

    India advancing as a global hub of affordable, quality healthcare solutions: Dr Jitendra Singh

    Unapproved drops for dry eyes pose risks: Govt

    Unapproved drops for dry eyes pose risks: Govt

    Semaglutide Patent Expires: Will Diabetes, Weight-Loss Treatment Become More Accessible For Patients?

    Semaglutide Patent Expires: Will Diabetes, Weight-Loss Treatment Become More Accessible For Patients?

    Inaugural Conference of ‘Critical Nephrology Society of India’ (CNSI) puts Best Foot Forward

    Inaugural Conference of ‘Critical Nephrology Society of India’ (CNSI) puts Best Foot Forward